Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZOW96)

• Drug Name: L-162313 Drug Info
• Synonyms: L-162,313; 151488-11-8; L-162313; CHEMBL288174; butyl 3-(4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)-5-isobutylthiophen-2-ylsulfonylcarbamate; 5,7-Dimethyl-2-ethyl-3-[[4-[2-(n-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]imidazo-[4,5-b]-pyridine; 5,7-Dimethyl-2-ethyl-3-[[4-[2(N-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]Imidazo[4,5,6]pyridine; L 162313; Lopac-L-1415; AC1O7G4F; Lopac0_000697; MLS002153426; SCHEMBL9132197; GTPL3936; C30H38N4O4S2; HMS3262K15

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6603900
  TTD Drug ID: DMZOW96

Molecule-Related Drug Atlas

Drug(s) Targeting Angiotensin II receptor type-2 (AGTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[4]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[5]
EMA-401	DMYOUB6	Peripheral neuropathy	8C0Z	Phase 2	[6]
MP-157	DM5VXWO	Hypertension	BA00-BA04	Phase 1	[7]
PMID25416646-Compound-Figure5-E	DMYO7VH	N. A.	N. A.	Patented	[8]
Phenylpyridine derivative 3	DMDT5JI	N. A.	N. A.	Patented	[8]
1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	DMGYZQ2	N. A.	N. A.	Patented	[8]
Fonsartan	DM15LAP	Hypertension	BA00-BA04	Discontinued in Phase 2	[9]
L-158282	DMKSEIY	N. A.	N. A.	Discontinued in Phase 2	[10]
TAK-591	DM25DB4	Hypertension	BA00-BA04	Discontinued in Phase 1	[11]

Drug(s) Targeting Angiotensin II receptor type-1 (AGTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[12]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[13]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[12]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[12]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[14]
Telmisartan	DMS3GX2	Hypertension	BA00-BA04	Approved	[15]
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[16]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[17]
Tasosartan	DMM13DI	Hypertension	BA00-BA04	Approved	[18]
Eprosartan	DM07K2I	Hypertension	BA00-BA04	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor type-1 (AGTR1)	TT8DBY3	AGTR1_HUMAN	Inhibitor	[2]
Angiotensin II receptor type-2 (AGTR2)	TTQVOEI	AGTR2_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3936).
• [2] Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem. 2008 Jul 15;16(14):6841-9.
• [3] Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition. Bioorg Med Chem. 2010 Jun 15;18(12):4570-90.
• [4] The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
• [5] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [6] Clinical pipeline report, company report or official report of Spinifex.
• [7] As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard
• [8] PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
• [9] Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43.
• [10] Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
• [11] Clinical pipeline report, company report or official report of Takeda (2009).
• [12] Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
• [13] Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
• [14] Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
• [15] Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
• [16] The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
• [17] Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
• [18] Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
• [19] Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.